| Abstract: | 我國預防接種救濟制度已運作逾34年，自110年起，國內推行大規模COVID-19疫苗接種政策，民眾申請案件數暴增，至111年9月止，COVID-19疫苗案件數總計近7,000多案，較疫情前5年平均申請數驟增40倍以上；再加上疫情持續嚴峻，各級衛生單位及醫療機構全力投入防疫，難以立即因應相關調查及資料蒐集工作，即使已盡力擴增審議量，以目前收到的申請案仍非短時間可審議完畢，導致民眾無法即時獲得救濟。再者，各個個案進入預防接種受害救濟審議小組（VICP）小組審查，也可能因為判斷因果關係之過於嚴苛，導致像是此類緊急授權之新冠疫苗，真正有更多救濟需求的人無法獲得妥適的補償。
本案研究將重新審視現行預防接種受害救濟制度，從制度之設置目的、保障範圍及承擔風險之主體進行適用性及優缺點分析，並蒐集國內外立法例、期刊、論文，法院判例等為參考，借鏡英、美、德、日及芬蘭等國家其各自之疫苗風險分擔機制，比較臺灣現行制度之優劣比較。同時，亦將舉行專家座談會或學術研討會，廣納學術界、保險實務界及醫界對於我國現行預防接種救濟制度之意見，最後再由風險管理與保險專業角度彙整及分析妥適的補償機制與運作模式，提出符合我國社會之制度設計與主管機關修正相關法令規定之參考，俾利維持預防接種受害救濟基金之永續運作，並提升制度運作效率，以維護民眾權益。
The vaccine injury compensation regime in Taiwan has been operated for more than 34 years. Taiwan has implemented COVID-19 vaccination policy since 2020, and the number of public application cases has skyrocketed. As of September 2022, the total number of COVID-19 vaccine cases which applied for compensation has reached nearly 7,000, and the average number of applications due to today has increased by more than 40 times after the epidemic. Due to the continued severity of the epidemic, medical institutions at all levels are fully committed to epidemic prevention, and it is difficult to respond to relevant investigations and data collection immediately, even if they have tried their best to expand the amount of deliberations in each meeting, the applications received so far cannot be deliberated in a short period of time, resulting in the inability of the public to obtain immediate relief. Furthermore, although individual cases are reviewed by the Vaccine Injury Compensation Program (VICP), people who really need more relief cannot obtain the compensation due to the strict judgment process.
This project will examine the current vaccine injury compensation regime, analyze the applicability and the advantages and disadvantages of the regime from the purpose of setting up the system, the scope of protection, to the subject of risk. Also, we will collect domestic and foreign legislation, periodicals, papers, and court cases, etc. as references, take a page out of the policies in United Kingdom, the United States, Germany, Japan, and Finland, and compare the advantages and disadvantages of Taiwan's current policy. At the same time, we will collect the opinions from the academia, the insurance industry and the medical profession by holding the symposiums. Last but not least, we will analyze the current compensation from the perspective of risk management and insurance professionals and propose a vaccine injury compensation regime which is in line with our society and relevant laws and regulations amended by competent authorities, so as to maintain the sustainable operation of the fund of vaccine injury compensation regime and improve the efficiency of the system operation to protect the rights and interests of the public. |
